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1. Introduction
Autoantibodies are groups of antibodies that are directed against body’s own antigen. These 
autoantibodies are generated against different types of antigens in various autoimmune dis-
eases. Clinical symptoms of systemic autoimmune diseases are characterized by the involve-
ment of various organs in addition to the production of non-organ specific autoantibodies. 
These autoantibodies in autoimmune diseases are associated with a specific clinical symptom 
within a spectrum [1]. Most of the autoantibodies have diagnostic and prognostic importance 
with respect to their associated disease and all of these are not involve in the pathogenesis of 
these diseases. Most autoantibodies are mainly used as biological markers for certain disease 
but they do not actually reflect the pathophysiological process underwent during the course 
of the disease, however, many autoantibodies also have a pathogenetic roles such as anti-
nuclear antibodies and anti-tTG antibodies in celiac disease. For example, autoimmune 
hepatitis is a chronic disease which is characterized by various clinical, histological as well as 
immunological characteristics including production of circulating autoantibodies and high 
serum concentration of gamma globulin [2]. These autoantibodies are very important for the 
correct diagnosis and classification of autoimmune liver disease [3] and they are not related 
with the pathogenesis of autoimmune hepatitis. However, some of the systemic autoimmune 
disease relating these autoantibodies in the sense that their levels are changes during the 
course of the disease. These include anti-double stranded DNA antibodies in systemic lupus 
erythematosus (SLE) and anti-neutrophil cytoplasmic autoantibodies in the vasculitis [4]. 
Other types of antibodies like anti-nucleosome and anti-CIq autoantibodies can function as 
both markers of the disease activity as well as pathogenic autoantibodies in SLE [5, 6].
The history of the autoantibodies goes back to 1940s, when two types of antibodies (anti-
nuclear antibodies; ANA and rheumatoid factors; RF) were discovered as the serum factors 
that bind to nuclear antigen IgG, respectively [7, 8]. ANA and RF considered being a diagnostic 
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feature of SLE but their role in disease pathogenesis remains elusive. In the last two decades, 
the effects of autoimmune diseases have been gown up to such an extent that it can explains 
both points of views, as clinically and diagnostically. The pathogenic mechanisms of these 
autoimmune diseases help to contribute to the discovery of new autoantibodies and new area 
of research, based on diagnostic and prognostic value, have been developed. Determination 
of these autoantibodies in the diagnosis of autoimmune disease is important because they 
are sometime showing nonspecific, unclear character and even shared by different autoim-
mune diseases [9]. For most of the autoimmune diseases, classification criteria include the 
determination of autoantibody that helps in final diagnosis. They are important not only for 
diagnostic perspective but also for prognostic value. Some of these autoimmune have been 
associated with the clinical manifestation of the disease, therefore estimation of these auto-
antibodies pattern in the patients might helpful to detect severity of the disease that can be 
useful for the need of correct therapy [10].
Several autoimmune diseases show chronic conditions that develop over the period of years 
and are characterized by the production of autoantibodies that actually present much before 
the actual onset of the disease. These autoantibodies are called as predictive autoantibodies 
that are present (or appear) in the blood much before systemic pathological conditions arise 
during the course of the disease. Detection of specific autoantibodies is the most important 
clinical and experimental evidence to predict any autoantibodies as biomarker for that auto-
immune disease [11]. The levels and variety of autoantibodies may vary according to the 
disease that may function as predictive biomarker. While the experimental importance of 
autoantibodies has been well recognized in many clinical conditions, its clinical utilization 
remains to be short for most of the diseases [12]. Autoimmune diseases are caused by vari-
ous autoimmune responses, generated during the course of the disease. The generations of 
immune responses are characterized by the appearance of the autoantibodies in the serum, 
therefore recognition of a particular autoantibody showed the path to recognize an autoim-
mune disease. Initially, the clinical symptoms of the disease are not emerges in full flash 
although these autoantibodies may arises much before these symptoms and actual onset of 
the disease. So, the symptoms are not visible, so the physician did not think to test these 
autoantibodies initially [13]. Therefore, test for these autoantibodies could be done in pre-
screening on various groups of population to identify the individuals who are susceptible for 
the development of the disease at an early stages and treatment should be given to prevent the 
actual occurrence of the disease. Multiple tests have been given for these patients for different 
autoimmune diseases, and recommendations are given to done multiple test for the patient 
who are having autoimmune disease [14]. However, disease related autoantibodies cannot 
develop simultaneously, although they are present much before the actual disease onset, and 
many of these autoantibodies are antigen specific, so using a panel of different autoantibodies 
set, might helpful to increase the sensitivity and prediction of the test [15].
Autoimmunity arises due to the failure of the immune system to be self-tolerance, which is 
mediated through the involvement of T and B cells [16]. Most of the autoimmune disease 
involves T cell, which play an important role in dysregulation and autoimmune aggres-
sion and during this process large amount of autoantibodies are also produced. These 
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autoantibodies plays not only in key pathogenic role in some diseases including SLE and 
Graves’ disease but also found in some disease in which they play minor pathogenic role 
and can act as important biomarker [17, 18]. Cytokines, in addition to the production of 
autoantibodies, play important role in the generation of autoimmune response (especially 
pro-inflammatory cytokines: except multiple sclerosis), they are produced in response to the 
viral invasion and are deeply involved in various autoimmune process. Under normal condi-
tion, anti-cytokine antibodies response have been develop in healthy normal individual that 
is consider to be normal physiological process to control various immune response. These 
responses are for limited time initially, and then the concentration of these autoantibodies 
increases, reaching a threshold and then coming up to its normal concentration after few 
weeks. This process also occurs in some pathological conditions including autoimmunity 
and autoantibodies develop as a result of these processes might be used as prognostic marker 
for monitoring the disease [19].
2. Different types of autoantibodies
2.1. Anti-cytokine autoantibodies
Autoantibodies against various types of cytokines have been described not only in normal 
individuals but also in patients with different infectious and immuno-inflammatory disease 
[20]. These include interferon (α, β, and γ), interleukin (α, 2, 4, 6, 8 and 10), nerve growth 
factor, chemokine (α and β), leukemia inhibitory factor, granulocyte-macrophage colony-
stimulating factor, and tumor necrosis factor (α and β) and receptor, which are found to be 
in normal individuals and patients with various disorders. In autoimmune disease, these 
autoantibodies can function as prognostic biomarkers that may even show negative (auto-
antibodies against IL-18 and IL-1α in RA) or positive (autoantibodies to IL-6 in systemic scle-
rosis) results [21]. The autoantibodies against cytokines found to be pathogenic that makes 
autoimmune patients more susceptible to other diseases. There are various autoimmune dis-
eases including rheumatoid arthritis, multiple sclerosis, systemic sclerosis, SLE, autoimmune 
polyendocrine syndrome type 1, in which neutralizing autoantibodies against cytokines have 
been described. The affinity of anti-cytokine autoantibodies may depend on the function of 
cytokine during various immune responses. For example, pro-inflammatory cytokines such 
as interleukin-1α, -6, -8, TNF-α and GM-CSF, have more frequently autoantibodies, whereas 
anti-inflammatory cytokines like interleukin-10 and TGF-β, have autoantibodies that were 
reported rarely [22–24]. However, most of these studies does not provide sufficient evidences 
for the functional effects of these autoantibodies, which might helpful to describe their role 
in various autoimmune diseases and capitalize them for future therapies. There are few pro-
inflammatory cytokines that play important role in joint aggression in rheumatoid arthritis 
[25, 26]. Autoantibodies against IL-1alpha can be worked as an important prognostic marker 
for early detection of RA [27] and several parameters of RA disease activity and severity was 
found to be significantly lower in those patients who have high levels of anti-IL-1α autoanti-
bodies in comparison to those who have low levels of these autoantibodies. Autoantibodies 
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showed neutralizing effects on the function of IL-1α by inhibiting thymocytes proliferation 
in the sera of RA patients [28]. These autoantibodies were also detected in the patients with 
systemic sclerosis. Autoantibodies against IL-1α have been secreted in high amount in the 
skin [29]. These autoantibodies have also been found in other dermal diseases; for example, 
psoriasis and pemphigus, that are supposed to be involve in the regulation of inflammation 
of skin [30].
2.2. Antinuclear autoantibodies (ANA)
Autoimmune hepatitis is the first disease in which autoantibodies had been clearly associ-
ated. In 1960s, these autoantibodies were detected by indirect immunofluorescence assay in 
the diagnosis and prognosis of autoimmune hepatitis. ANA directed against various nuclear 
components including single or double stranded DNA (s- or ds-DNA), transfer RNA, histone 
and other nuclear components [31–33]. There are various other nuclear components which 
are targeted by these autoantibodies but are not related with autoimmune hepatitis includ-




, cyclin A, and centromere of the 
chromosomes [34]. These autoantibodies may arise due to the mistake in identifying normal 
nuclear components as foreign and dangerous. Once this happen, they identify natural occur-
ring protein as foreign and they are called as autoantibodies because they are produce against 
own antigen. These autoantibodies start chains of reactions causing inflammation and attack 
itself. So they also start to target normal protein in the nucleus of the cell and they are called 
antinuclear antibodies. Although, we all have autoantibodies but they are present in very small 
amount and they remain silent in the body until and unless some factors may trigger these 
autoantibodies to be active against normal nuclear components. Once these autoantibodies 
attack on the self nuclear components, they may trigger various diseases including systemic 
lupus erythematosus, scleroderma, Sjogren’s syndrome, polymyositis/dermatomyositis, etc. 
Increased level of ANA is seen in almost all the systemic rheumatic disease which either 
showed sometime high, sometime loose association between a particular type of ANA and 
a particular type of rheumatic disease. Most of these autoantibodies directed against either 
nucleic acids or protein close to the nucleic acid. For example, the most common antigen in 
SLE is nucleosomes. Nucleosomes form the building blocks of chromatin molecule and play 
an important role in the compaction of DNA in the nucleus. ANA directed against DNA, con-
sidered to be as diagnostic maker and hallmark of SLE. Antibodies against histones were also 
reported in various studies that also proven to be an important marker for SLE. Other impor-
tant antigen for ANA is small nuclear ribonucleoprotein (snRNP) particles that are formed 
from a capped small nuclear RNA molecule and polypeptide. In addition, other antigens 
from the cytoplasmic relevance to ANA binding are ribosomal RNP and aminoacyl tRNA 
synthetase [35]. ANA play an active role in SLE since these autoantibodies bind to the antigen 
that may be present in the circulation or their immune complexes are deposited in the tissue 
that leads to inflammation and subsequent disease features. Either anti-DNA or anti-DNA 
complexes were involved in the induction of lupus nephritis. In addition, anti-DNA antibod-
ies against various protein molecules are also found in SLE that plays an important role in the 
etiopathogenesis of this disease [36–40].
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2.3. Anti-citrullinated protein antibodies and anti-CCP antibodies
These are the autoantibodies that are induced against any peptide or protein that are citrul-
linated. They are present in the majority of the patients suffering from RA. Clinically, this 
antigen can be frequently used to detect antibodies in the serum of RA patients. It has been 
assumed that high titers of these autoantibodies are correlated with high risk in the devel-
opment of RA [41]. These autoantibodies were found to be highly sensitive and specific in 
comparison to rheumatoid factor. In addition, combined estimation of rheumatoid factor and 
anti-citrulline antibodies can increase the assessment of both tests [41]. Anti-CCP antibodies 
can function not only as diagnostic marker but also have prognostic value, they might be used 
to predict the development of the disease and can be present much before the actual onset of 
the disease. These autoantibodies are also associated with other diseases such as cardiovas-
cular as well as pulmonary complications. Anti-CCP antibodies can be useful in the diagnosis 
and prognosis of RA and have been included as one of the major criteria for the classification 
of this disease [42].
2.4. Rheumatoid factor (RF)
Rheumatoid arthritis is one of the disease in which the option for diagnosis and prognosis 
is more advance in the field of autoimmunity [43]. Since RA have nonspecific symptoms, 
therefore the diagnosis could be difficult but early diagnosis is important to have more option 
for therapy and cure. However, as this disease is characterized by radiological progression 
during early phase of the disease, so there might be good opportunity to initiate for early 
and effective treatment [44]. In early studies, serological diagnostic tool for RA were limited 
and the only autoantibodies related with the diagnosis of RA was rheumatoid factor that 
showed low sensitivity and specificity [43, 44]. Some patients can even showed negativity for 
RF and RF may be positive in various other autoimmune diseases that are showing nonclini-
cal conditions and are positive even with other types of autoantibodies in these diseases. If 
the RF is falsely positive, it is interesting to mention that the complementary diagnostic test 
is antistreotolysin O (ASO/ASLO) test. Earlier studies have shown that smoker have elevated 
incidence of RA because of high RF [45]. Studies also indicated that elevated level of RF was 
found to be twice in comparison to both current and ex-smokers than nonsmokers and the 
level of RF was more in these individual [46]. Studies also have shown that smoking somehow 
effect the progression of RA [47].
Besides that, there are large groups of autoantibodies that are causing various types of autoim-
mune diseases including Anti-transglutaminase antibodies-celiac disease, dermatitis herpeti-
formis; Anti-ganglioside antibodies-Miller-Fisher syndrome, acute motor axonal neuropathy; 
Anti-actin antibodies-coeliac disease; Anti-thrombin antibodies-SLE; Anti-neutrophil cyto-
plasmic antibody-polyangiitis; Anti-smooth muscles antibodies-hepatitis; Anti-mitochondrial 
antibodies-primary biliary cirrhosis; Anti-SRP-polymyositis; Anti-SRP & Anti-AChR-
myasthenia gravis; Anti-thyroid antibodies-Hashimoto’s thyroiditis, Graves’ disease; Anti-
SLA/LP, perinuclear anti-cytoplasmic antibodies, Anti-LKM, Anti-LC-1, Anti-mitochondrial 
antibodies, Anti-asialoglycoprotein receptor antibodies-liver disease, etc. (Figure 1).




Autoantibodies are group of antibodies that are directed against self antigen. These antibodies 
recognized normal molecules in the cells as foreign and dangerous. As a result of that, large 
group of reactions take place in which these autoantibodies recognized normal molecules and 
generate various immunological response against them. In consequence, these autoantibodies 
also interact with other protein molecule in order to generate a series of reactions causing 
binding to the self molecules. Binding of autoantibodies to self molecules can be recognized 
by various immune cells that mainly responsible for the damage and excretion of these mol-
ecules. For examples, there are various types of autoantibodies and their associated antigens 
found in in SLE (Table 1). These self damaged molecules are called as auto-antigen and finally 
treat as foreign molecule and damage by various immune cells.
Figure 1. List of some common autoantibodies and their associated diseases.
Antinuclear autoantibodies (ANA) Various nuclear components
Anti-ds DNA Double stranded DNA
Anti-Sm Protein with nuclear U1 RNA
Anti-RNP Protein with U1 RNAγ
Anti-R○ (SS-A) Protein with hYRNA
Anti-La (SS-B) Protein with hYRNA
Anti-histone Histones
Anti-phospholipids Phospholipids
Anti-neuronal Neurons and lymphocytes
Anti-ribosomal Protein in ribosomes
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